Stock Research: Journey Medical Corporation

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Journey Medical Corporation

NAQ:DERM US48115J1097
21
  • Value
    46
  • Growth
    14
  • Safety
    Safety
    55
  • Combined
    26
  • Sentiment
    49
  • 360° View
    360° View
    21
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

more

ANALYSIS: With an Obermatt 360° View of 21 (better than 21% compared with alternatives), overall professional sentiment and financial characteristics for the stock Journey Medical Corporation are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Journey Medical Corporation. The only rank that is above average is the consolidated Safety Rank at 55, which means that the company has a financing structure that is safer than those of 55% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 46, which means that the share price of Journey Medical Corporation is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 14, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 49, which means that professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-Jul-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 32 30 99
Growth
14 39 89 41
Safety
Safety
55 30 8 43
Sentiment
49 28 15 24
360° View
360° View
21 9 17 54
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 74 46 51
Opinions Change
50 50 50 50
Pro Holdings
n/a 18 55 24
Market Pulse
29 31 5 46
Sentiment
49 28 15 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
46 32 30 99
Growth
14 39 89 41
Safety Safety
55 30 8 43
Combined
26 9 28 80
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
80 76 69 92
Price vs. Earnings (P/E)
18 80 80 80
Price vs. Book (P/B)
31 13 5 94
Dividend Yield
1 1 1 1
Value
46 32 30 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
82 89 6 89
Profit Growth
23 1 84 75
Capital Growth
4 10 95 7
Stock Returns
31 79 100 33
Growth
14 39 89 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
28 34 22 29
Refinancing
79 45 9 19
Liquidity
47 43 20 96
Safety Safety
55 30 8 43

Similar Stocks

Discover high‑ranked alternatives to Journey Medical Corporation and broaden your portfolio horizons.

Constellation Energy

NSQ:CEG
Country: USA
Industry: Electric Utilities
Size: X-Large
Full Stock Analysis

D.R. Horton

NYQ:DHI
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The only above-average rank is Safety. All other ranks (Value, Growth, and Sentiment) are below average. As Safety is the least critical rank, there are few positive facts to support this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: